Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. SciClone Pharmaceuticals (Holdings) Limited
  6. News
  7. Summary
    6600   KYG4271B1023

SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

(6600)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SciClone Pharmaceuticals : Pharma tests hepatitis drug as COVID-19 vaccine enhancer

04/26/2021 | 03:51am EDT

BEIJING (Reuters) - China's SciClone Pharmaceuticals has begun a clinical trial to test if its hepatitis B treatment Zadaxin helps to boost immunity provided by COVID-19 vaccines, it said on Monday.

SciClone said it is using an inactivated COVID-19 vaccine in its trial but did not specify which one. Three coronavirus vaccines approved in China use inactivated virus and have been developed by China National Pharmaceutical Group (Sinopharm) and Sinovac Biotech.

"In view of the mechanism of action of Thymalfasin (Zadaxin) and previous clinical studies, the combination with Thymalfasin may help increase the level of SAR-Cov-2 neutralizing antibody and prolong the antibody protection time," it said in a statement.

The company plans to recruit 200 trial participants across China and evaluate the safety and ability to elicit immune responses from the vaccine when combined with Zadaxin.

It said the drug has been approved as a vaccine enhancer for the treatment of patients with chronic hepatitis B and immune impairment.

(Reporting by Roxanne Liu and Ryan Woo; Editing by David Goodman)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED 0.00% 14.28 End-of-day quote.0.00%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
All news about SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
06/22MARKET CHATTER : Medlive Technology Passes Hong Kong Listing Hearing
MT
06/10MARKET CHATTER : US-Based Biohaven Pharma Mulls Spinoff, Separate Listing of APA..
MT
06/01MARKET CHATTER : China's Neusoft Medical Files for Hong Kong IPO
MT
05/14SCICLONE PHARMACEUTICALS  : Form of proxy for the annual general meeting to be h..
PU
05/13SCICLONE PHARMACEUTICALS  : Proposed election and re-election of directors and p..
PU
04/27MARKET CHATTER : China's Clover Biopharmaceuticals Files for Hong Kong IPO
MT
04/26SCICLONE PHARMACEUTICALS  : Pharmaceutical Begins Clinical Study for COVID-19 In..
MT
04/26SCICLONE PHARMACEUTICALS  : Pharma tests hepatitis drug as COVID-19 vaccine enha..
RE
04/25SCICLONE PHARMACEUTICALS  : Voluntary Announcement - Official Initiation of the ..
PU
04/23SCICLONE PHARMACEUTICALS  : Pharma Officially Begins Cooperation with Shanghai S..
MT
More news
Financials
Sales 2021 2 434 M 377 M 377 M
Net income 2021 801 M 124 M 124 M
Net cash 2021 689 M 107 M 107 M
P/E ratio 2021 10,4x
Yield 2021 6,17%
Capitalization 8 070 M 1 247 M 1 248 M
EV / Sales 2021 3,03x
EV / Sales 2022 2,47x
Nbr of Employees 790
Free-Float 56,0%
Chart SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Duration : Period :
SciClone Pharmaceuticals (Holdings) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 11,90 CNY
Average target price 17,16 CNY
Spread / Average Target 44,2%
EPS Revisions
Managers and Directors
NameTitle
Hong Zhao President, CEO & Executive Director
Zhen Fu Li Chairman
Ping Chen Independent Non-Executive Director
Wendy Hayes Independent Non-Executive Director
Guo En Liu Independent Non-Executive Director
Sector and Competitors